中国临床药理学杂志2024，Vol.40Issue(8)：1131-1135,5.DOI:10.13699/j.cnki.1001-6821.2024.08.009
恩格列净与利格列汀治疗2型糖尿病合并心力衰竭患者的临床研究
Clinical trial of empagliflozin and linagliptin in the treatment of patients with type 2 diabetes mellitus with heart failure
程光慧 1李新军 1李迎婕 2翟双久美 1王慧 1崔丹丹 1张海洋 3王紫监4
作者信息
- 1. 河北北方学院附属第二医院心内一科,河北张家口 075100
- 2. 河北北方学院附属第二医院肾内科,河北张家口 075100
- 3. 河北北方学院附属第二医院心内二科,河北张家口 075100
- 4. 河北北方学院附属第二医院心内三科,河北张家口 075100
- 折叠
摘要
Abstract
Objective To compare the efficacy and safety of empagliflozin and linagliptin in the treatment of patients with type 2 diabetes mellitus(T2DM)with heart failure(HF).Methods Patients with T2DM and HF were randomly into control group and treatment group.Both groups were treated with individualized anti-HF and metformin-based hypoglycemic therapy.On this basis,the control group was given linagliptin orally(5 mg each time,once a day),while the treatment group was given oral administration of empagliflozin 10 mg every day.Patients in both groups were treated continuously for 6 months.The clinical efficacy and blood glucose indicators[fasting blood glucose(FBG),2 h postprandial blood glucose(2 h PBG),hemoglobin A1c(HbA1c)],cardiac molecular markers[N-terminal pro-brain natriuretic peptide(NT-proBNP),fibroblast growth factor 23(FGF23),copeptin(CPP)]and caridac function indicators[left ventricular end-diastolic diameter(LVEDD),left ventricular ejection fraction(LVEF),left ventricular remodeling index(LVRI)]before and after treatment were compared,and the adverse drug reactions were recorded.Results There were 40 cases in treatment group and 40 cases in control group.After treatment,the total effective rates in treatment group and control group were 97.50％(39 cases/40 cases)and 80.00％(32 cases/40 cases),with no significant difference(P＜0.05).The FBG levels in treatment group and control group were(7.64±1.18)and(7.83±1.24)mmol·L-1;2 h PBG levels were(8.97±1.46)and(9.04±1.35)mmol·L-1;HbA1c levels were(7.58±1.27)％and(7.65±1.42)％,all with no significant difference(all P＞0.05).The NT-proBNP levels in treatment group and control group were(612.53±204.62)and(1 045.24±316.75)pg·mL-1;FGF23 levels were(362.74±62.61)and(493.27±74.64)μg·L-1;CPP levels were(12.58±3.43)and(16.87±4.36)pmol·L-1;LVEDD values were(51.19±2.36)and(53.35±2.24)mm;LVEF values were(52.69±3.38)％and(50.28±3.75)％;LVRI values were(2.62±0.29)and(2.96±0.33)kg·L-1,all with significant difference(all P＜0.05).The incidence rates of adverse reactions in treatment group and control group were 5.00％(2 cases/40 cases)and 10.00％(4 cases/40 cases),with no significant difference(P＞0.05).Conclusion Both empagliflozin and linagliptin can effectively reduce the blood glucose in patients with T2DM complicated with HF.Empagliflozin can better promote the improvement of cardiac function in patients without significantly increase the incidence of adverse drug reactions.关键词
恩格列净/利格列汀/2型糖尿病/心力衰竭/N末端脑钠肽前体/成纤维细胞生长因子/和肽素Key words
empagliflozin/linagliptin/type 2 diabetes mellitus/heart failure/N-terminal pro-brain natriuretic peptide/fibroblast growth factor 23/copeptin分类
医药卫生引用本文复制引用
程光慧,李新军,李迎婕,翟双久美,王慧,崔丹丹,张海洋,王紫监..恩格列净与利格列汀治疗2型糖尿病合并心力衰竭患者的临床研究[J].中国临床药理学杂志,2024,40(8):1131-1135,5.
